 ANDOVER, Mass., May 4, 2021 PRNewswire -- TransMedics Group, Inc. TransMedics Nasdaq: TMDX, a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2021. 